Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, Abrisqueta P, Giraldo P, Martínez R, Yáñez L, Terol MJ, González M, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC). García-Marco JA, et al. Among authors: giraldo p. Med Clin (Barc). 2017 Apr 21;148(8):381.e1-381.e9. doi: 10.1016/j.medcli.2016.12.030. Epub 2017 Feb 22. Med Clin (Barc). 2017. PMID: 28236475 English, Spanish.
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M. Santamaría C, et al. Among authors: giraldo p. Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24. Haematologica. 2008. PMID: 18815192 Free article.
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL. García-Gutiérrez V, et al. Among authors: giraldo p. Am J Hematol. 2014 Nov;89(11):E206-11. doi: 10.1002/ajh.23816. Epub 2014 Aug 27. Am J Hematol. 2014. PMID: 25059397 Free article.
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Steegmann JL, et al. Among authors: giraldo p. J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. J Cancer Res Clin Oncol. 2017. PMID: 28551768 Free PMC article.
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Steegmann JL, et al. Among authors: giraldo p. J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188. doi: 10.1007/s00432-017-2532-1. J Cancer Res Clin Oncol. 2018. PMID: 29063181 Free PMC article.
[Systemic mastocytosis. Study of 14 cases].
García-Erce JA, Giraldo P, de Vicente P, Alvarez R, Losfablos F, Velilla J, Mayayo P, Rubio-Félix D, Giralt M. García-Erce JA, et al. Among authors: giraldo p. Med Clin (Barc). 1998 Oct 24;111(13):499-502. Med Clin (Barc). 1998. PMID: 9859067 Spanish.
Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients.
Quijano S, López A, Rasillo A, Barrena S, Luz Sánchez M, Flores J, Fernández C, Sayagués JM, Osuna CS, Fernández N, González M, Giraldo P, Giralt M, Pérez MC, Martin-Antoran JM, Gutiérrez O, Perdiguer L, Díaz Mediavilla J, González Silva M, Asensio Del Rio A, Cerveró C, Guerra JL, Butrón R, García Mdel C, Almeida J, Orfao A. Quijano S, et al. Among authors: giraldo p. Blood. 2008 May 15;111(10):5130-41. doi: 10.1182/blood-2007-10-119289. Epub 2008 Mar 12. Blood. 2008. PMID: 18337555 Free article.
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodríguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel J, González M. Santamaría C, et al. Among authors: giraldo p. Ann Hematol. 2010 May;89(5):453-8. doi: 10.1007/s00277-009-0864-x. Epub 2009 Nov 27. Ann Hematol. 2010. PMID: 19943049
[Guidelines for type 1 Gaucher's disease].
Giraldo P; Grupo de Trabajo de las Guías de Actuación. Giraldo P, et al. Med Clin (Barc). 2011 Sep;137 Suppl 1:55-60. doi: 10.1016/S0025-7753(11)70019-7. Med Clin (Barc). 2011. PMID: 22230128 Spanish.
395 results